View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Compass Diversified Declares Second Quarter 2024 Distributions on Comm...

Compass Diversified Declares Second Quarter 2024 Distributions on Common and Series A, B and C Preferred Shares WESTPORT, Conn., July 02, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that its Board of Directors (the “Board”) has declared a quarterly cash distribution of $0.25 per share on the Company’s common shares (the “Common Shares”). The distribution for the three months ended June 30, 2024, is payable on July 25, 2024, to all holders of record of Common Shares as of July 18, 2024. ...

Daniel Ives ... (+4)
  • Daniel Ives
  • John Katsingris
  • Sam Brandeis
  • Steven Wahrhaftig
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 28, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 20, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafen...

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomized Stage 1 readout for naporafenib plus trametinib vs. trametinib monotherapy expected in 2025 SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-sta...

Funko Inc: 3 directors

Three Directors at Funko Inc sold after exercising options/sold 44,077 shares at between 10.094USD and 10.266USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...

 PRESS RELEASE

Mission Produce™ Announces Fiscal 2024 Second Quarter Financial Result...

Mission Produce™ Announces Fiscal 2024 Second Quarter Financial Results Achieves record second quarter results driven by higher price and volume in the Marketing & Distribution segment OXNARD, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (Nasdaq: AVO) (“Mission” or the “Company”), a world leader in sourcing, producing, and distributing fresh Hass avocados with additional offerings in mangos and blueberries, today reported its financial results for the fiscal second quarter ended April 30, 2024. Fiscal Second Quarter 2024 Financial Overview: Total revenue increased ...

Coty Inc.: Covenant Quality Post-Sale Snapshot: €500m 4.500% Senior Se...

Coty Inc.'s covenant package provides lower-tier weak protection, reflecting a CQ score of 4.03.

Coty Inc. - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 1, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Compass Diversified Holdings: 5 directors

Five Directors at Compass Diversified Holdings bought 37,956 shares at between 22.406USD and 22.411USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...

 PRESS RELEASE

Erasca to Present at Upcoming Investor Conferences in June

Erasca to Present at Upcoming Investor Conferences in June SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings. Jefferie...

 PRESS RELEASE

Coty Inc. to Present at Upcoming Investor Events

NEW YORK--(BUSINESS WIRE)-- Coty Inc. (NYSE: COTY) (Paris: COTY), one of the world’s largest beauty companies, announced that its company executives will present at upcoming investor events. Wednesday, June 5: Deutsche Bank Global Consumer Conference – Sue Nabi, Chief Executive Officer and Laurent Mercier, Chief Financial Officer, will present at 10:30 am CET in Paris, France. A webcast of the presentation and fireside chat will be available in the “Events & Presentations” section at . Thursday, June 13: Evercore ISI Virtual Consumer & Retail Conference – Sue Nabi, Chief Executive Offic...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch